AU4028895A - Vaccine and treatment method of Human Immunodeficiency Virus - Google Patents
Vaccine and treatment method of Human Immunodeficiency VirusInfo
- Publication number
- AU4028895A AU4028895A AU40288/95A AU4028895A AU4028895A AU 4028895 A AU4028895 A AU 4028895A AU 40288/95 A AU40288/95 A AU 40288/95A AU 4028895 A AU4028895 A AU 4028895A AU 4028895 A AU4028895 A AU 4028895A
- Authority
- AU
- Australia
- Prior art keywords
- vaccine
- treatment method
- immunodeficiency virus
- human immunodeficiency
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14041—Use of virus, viral particle or viral elements as a vector
- C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71415291A | 1991-06-11 | 1991-06-11 | |
| US714152 | 1991-06-11 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU21931/92A Division AU2193192A (en) | 1991-06-11 | 1992-06-10 | Vaccine and treatment method of human immunodeficiency virus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU4028895A true AU4028895A (en) | 1996-02-22 |
Family
ID=24868938
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU21931/92A Abandoned AU2193192A (en) | 1991-06-11 | 1992-06-10 | Vaccine and treatment method of human immunodeficiency virus infection |
| AU40288/95A Abandoned AU4028895A (en) | 1991-06-11 | 1995-12-07 | Vaccine and treatment method of Human Immunodeficiency Virus |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU21931/92A Abandoned AU2193192A (en) | 1991-06-11 | 1992-06-10 | Vaccine and treatment method of human immunodeficiency virus infection |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP0542998A1 (en) |
| JP (1) | JPH06501851A (en) |
| CN (1) | CN1068266A (en) |
| AU (2) | AU2193192A (en) |
| BG (1) | BG97519A (en) |
| CA (1) | CA2087732A1 (en) |
| EE (1) | EE9400183A (en) |
| FI (1) | FI930577A (en) |
| HU (1) | HUT68355A (en) |
| IE (1) | IE921875A1 (en) |
| IL (1) | IL102092A (en) |
| LT (1) | LT3365B (en) |
| MX (1) | MX9202781A (en) |
| PL (1) | PL297849A1 (en) |
| PT (1) | PT100584A (en) |
| SK (1) | SK18993A3 (en) |
| WO (1) | WO1992022654A1 (en) |
| ZA (1) | ZA924150B (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE40786E1 (en) * | 1984-03-16 | 2009-06-23 | The United States Of America As Represented By The Secretary Of The Army | Vaccines against intracellular pathogens using antigens encapsulated within biodegradable-biocompatible microspheres |
| US6479055B1 (en) | 1993-06-07 | 2002-11-12 | Trimeris, Inc. | Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission |
| US6017536A (en) * | 1993-06-07 | 2000-01-25 | Trimeris, Inc. | Simian immunodeficiency virus peptides with antifusogenic and antiviral activities |
| US5464933A (en) | 1993-06-07 | 1995-11-07 | Duke University | Synthetic peptide inhibitors of HIV transmission |
| WO1995017515A1 (en) | 1993-12-23 | 1995-06-29 | University Technologies International Inc. | Methods of expressing proteins in insect cells and methods of killing insects |
| AU723537B2 (en) | 1995-06-07 | 2000-08-31 | Trimeris Inc. | The treatment of HIV and other viral infections using combinatorial therapy |
| US6395541B1 (en) | 1996-05-23 | 2002-05-28 | The Rockefeller University | Methods for the identification of compounds capable of inhibiting HIV-1 viral replication employing murine cell lines expressing human topoisomerase I |
| US6319504B1 (en) | 1996-06-24 | 2001-11-20 | University Of Maryland Biotechnology Institute | Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin |
| US6077662A (en) * | 1996-11-27 | 2000-06-20 | Emory University | Virus-like particles, methods and immunogenic compositions |
| US6214540B1 (en) | 1997-03-26 | 2001-04-10 | University Of Maryland Biotechnology Institute | Chemokines that inhibit immunodeficiency virus infection and methods based thereon |
| US6583109B1 (en) | 1997-06-24 | 2003-06-24 | Robert C. Gallo | Therapeutic polypeptides from β-hCG and derivatives |
| US6548631B1 (en) | 1997-09-16 | 2003-04-15 | BIOMéRIEUX, INC. | Macrophage derived chemokine (MDC) as an anti-viral agent for the treatment and prevention of lentivirus infection |
| US6750008B1 (en) | 1999-07-09 | 2004-06-15 | Trimeris, Inc. | Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission |
| US7994278B1 (en) | 1999-08-06 | 2011-08-09 | Nobel Biosciences Llc | Biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA) |
| US6623741B1 (en) | 2000-02-29 | 2003-09-23 | Trimeris, Inc. | Methods and compositions for inhibition of membrane fusion-associated events including RSV transmission |
| AUPS065002A0 (en) | 2002-02-20 | 2002-03-14 | Immunaid Pty Ltd | Strategy for retroviral immunotherapy |
| EP1578766B1 (en) * | 2002-12-03 | 2013-02-13 | University of Massachusetts | Polyvalent, primary hiv-1 glycoprotein dna vaccines and vaccination methods |
| EP2270511A3 (en) | 2003-10-24 | 2011-08-24 | Immunaid Pty Ltd | Method of therapy |
| PA8809601A1 (en) | 2007-12-24 | 2009-07-23 | Cipla Ltd | ANTI-RETROVIRAL COMBINATION |
| ES2548508T3 (en) | 2009-05-27 | 2015-10-19 | Biotempus Limited | Disease treatment methods |
| KR101911229B1 (en) | 2011-08-19 | 2018-10-24 | 임모탈 스피릿 리미티드 | Antibody and antibody-containing composition |
| CN102961760B (en) * | 2011-09-01 | 2017-07-18 | 常州文松生物技术有限公司 | Overlapping peptide is used as reagent and its application for preparing Skin-test and detection specific cellular immunity |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL89118A0 (en) * | 1988-02-03 | 1989-08-15 | Microgenesys Inc | Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1 |
-
1992
- 1992-06-03 IL IL10209292A patent/IL102092A/en not_active IP Right Cessation
- 1992-06-08 ZA ZA924150A patent/ZA924150B/en unknown
- 1992-06-10 PL PL29784992A patent/PL297849A1/en unknown
- 1992-06-10 WO PCT/US1992/004980 patent/WO1992022654A1/en not_active Application Discontinuation
- 1992-06-10 AU AU21931/92A patent/AU2193192A/en not_active Abandoned
- 1992-06-10 EP EP92913889A patent/EP0542998A1/en not_active Withdrawn
- 1992-06-10 JP JP5501040A patent/JPH06501851A/en active Pending
- 1992-06-10 MX MX9202781A patent/MX9202781A/en unknown
- 1992-06-10 SK SK18993A patent/SK18993A3/en unknown
- 1992-06-10 CA CA002087732A patent/CA2087732A1/en not_active Abandoned
- 1992-06-10 HU HU9300686A patent/HUT68355A/en unknown
- 1992-06-11 CN CN92104517A patent/CN1068266A/en active Pending
- 1992-06-11 PT PT100584A patent/PT100584A/en not_active Application Discontinuation
- 1992-07-01 IE IE187592A patent/IE921875A1/en not_active Application Discontinuation
-
1993
- 1993-02-10 FI FI930577A patent/FI930577A/en not_active Application Discontinuation
- 1993-02-11 LT LTIP335A patent/LT3365B/en not_active IP Right Cessation
- 1993-03-10 BG BG97519A patent/BG97519A/en unknown
-
1994
- 1994-09-21 EE EE9400183A patent/EE9400183A/en unknown
-
1995
- 1995-12-07 AU AU40288/95A patent/AU4028895A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| LT3365B (en) | 1995-07-25 |
| LTIP335A (en) | 1995-01-31 |
| ZA924150B (en) | 1993-02-24 |
| HU9300686D0 (en) | 1993-06-28 |
| SK18993A3 (en) | 1993-10-06 |
| EP0542998A1 (en) | 1993-05-26 |
| IE921875A1 (en) | 1992-12-16 |
| HUT68355A (en) | 1995-06-28 |
| EE9400183A (en) | 1995-12-15 |
| FI930577A0 (en) | 1993-02-10 |
| PL297849A1 (en) | 1994-01-24 |
| FI930577A (en) | 1993-03-24 |
| IL102092A (en) | 1996-11-14 |
| MX9202781A (en) | 1993-04-01 |
| PT100584A (en) | 1993-07-30 |
| WO1992022654A1 (en) | 1992-12-23 |
| JPH06501851A (en) | 1994-03-03 |
| CN1068266A (en) | 1993-01-27 |
| AU2193192A (en) | 1993-01-12 |
| BG97519A (en) | 1994-03-24 |
| CA2087732A1 (en) | 1992-12-12 |
| IL102092A0 (en) | 1993-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU4028895A (en) | Vaccine and treatment method of Human Immunodeficiency Virus | |
| EP0831873A4 (en) | The treatment of hiv and other viral infections using combinatory therapy | |
| AU4750390A (en) | Virus inactivated blood product and method | |
| AU2326892A (en) | Acylmercaptoalkanoyldipeptides, methods of preparation and their therapeutic use | |
| AU1577792A (en) | Implantation tissue and treatment and use methods | |
| AU5041590A (en) | Combination wheelchair and walker apparatus | |
| ZA936592B (en) | Nutrition for persons infected with human immunodeficiency virus | |
| HU9302642D0 (en) | Gp 160-derivatives and vaccine containing them or gp-160 itself | |
| HU9202095D0 (en) | Therapy and vaccine against aids | |
| AU5848794A (en) | Multiple-gene mutants of human immunodeficiency virus (hiv) for vaccine use | |
| EP0726775A4 (en) | Vaccine and method for treatment of chlamydial infections | |
| EP0382551A3 (en) | Prevention and treatment of herpes virus infections | |
| AU1898792A (en) | Treatment or therapeutic booth for energetic, cosmetic and medical purposes | |
| IL102815A0 (en) | Pharmaceutical compositions and method for the treatment of infection caused by the human immunodeficiency virus | |
| AU4767896A (en) | Human immunodeficiency virus transcription inhibitors and methods of their use | |
| AU6877991A (en) | A method of inactivating human immunodeficiency virus | |
| EP0655919A4 (en) | Treatment of human viral infections. | |
| AU2653292A (en) | Method of lengthening and thickening human hair | |
| AU3593095A (en) | Method of treatment of human immunodeficiency virus (hiv) infection | |
| GB9111885D0 (en) | Nerve growth factor for use in the prevention and treatment of viral infections | |
| AU4660889A (en) | Method of treatment of human immunodeficiency virus | |
| PH27412A (en) | Method of treatment of human immunodeficiency virus | |
| AU6447690A (en) | Method of administering soluble t4 for treatment of human immunodeficiency virus infection | |
| AU6247896A (en) | Method for preparing sulphate esters effective in the treatment of hiv (human immunodeficiency virus) infections, and aids | |
| AU3053595A (en) | Therapeutic treatment and preparations |